Global Cell And Gene Therapy Clinical Trials Market Report

Description

List of Tables

The global demand for Cell And Gene Therapy Clinical Trials Market is presumed to reach the market size of nearly USD 52.93 BN by 2030 from USD 9.72 BN in 2022 with a CAGR of 20.72% under the study period 2023 - 2030.

Cell and gene therapies clinical trials have quickly emerged as one of the most transformative innovations in biopharmaceuticals. CGTs are tested in therapeutic areas beyond their initial oncology focus, including neurology and ophthalmology treatment. Cell and gene therapy clinical trials present a new wave of innovation in the life sciences industry.

MARKET DYNAMICS:

The rise in the CGT pipeline is the root cause fuelling the market growth rate. Also, increasing funding, investments in research and development, and successful product launches are boosting the market growth. Moreover, the market of cell and gene therapy clinical trials has witnessed significant growth over the past few years, with pharma firms partnering to create effective and accessible therapies for patients. Furthermore, cell and gene therapy clinical studies increased significantly compared to last year, as researchers are now shifting their focus to gene therapy because of its potential to treat cancer or rare diseases. This shift is expected to fuel the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cell and gene therapy clinical trials. The growth and trends of cell and gene therapy clinical trials industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the cell and gene therapy clinical trials market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Phase

Phase I
Phase II
Phase III
Phase IV

By Indication

Oncology
Cardiology
CNS
Musculoskeletal
Infectious Diseases
Dermatology
Endocrine, Metabolic, Genetic
Immunology & Inflammation
Ophthalmology
Hematology
Gastroenterology
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Cell And Gene Therapy Clinical Trials market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cell and gene therapy clinical trials market include IQVIA, ICON Plc, Laboratory Corporation of America Holdings, Charles River Laboratories International, Inc., PAREXEL International Corp., Syneos Health, Medpace, Holdings, Inc., PPD Inc., Novotech, Veristat LLC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11218697

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . CELL AND GENE THERAPY CLINICAL TRIALS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Phase
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET ANALYSIS BY PHASE

6.1 Overview by Phase
6.2 Historical and Forecast Data
6.3 Analysis by Phase
6.4 Phase I Historic and Forecast Sales by Regions
6.5 Phase II Historic and Forecast Sales by Regions
6.6 Phase III Historic and Forecast Sales by Regions
6.7 Phase IV Historic and Forecast Sales by Regions

7 . GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET ANALYSIS BY INDICATION

7.1 Overview by Indication
7.2 Historical and Forecast Data
7.3 Analysis by Indication
7.4 Oncology Historic and Forecast Sales by Regions
7.5 Cardiology Historic and Forecast Sales by Regions
7.6 CNS Historic and Forecast Sales by Regions
7.7 Musculoskeletal Historic and Forecast Sales by Regions
7.8 Infectious Diseases Historic and Forecast Sales by Regions
7.9 Dermatology Historic and Forecast Sales by Regions
7.10. Endocrine, Metabolic, Genetic Historic and Forecast Sales by Regions
7.11 Immunology & Inflammation Historic and Forecast Sales by Regions
7.12 Ophthalmology Historic and Forecast Sales by Regions
7.13 Hematology Historic and Forecast Sales by Regions
7.14 Gastroenterology Historic and Forecast Sales by Regions
7.15 Others Historic and Forecast Sales by Regions

8 . GLOBAL CELL AND GENE THERAPY CLINICAL TRIALS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE CELL AND GENE THERAPY CLINICAL TRIALS COMPANIES

9.1. Cell And Gene Therapy Clinical Trials Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF CELL AND GENE THERAPY CLINICAL TRIALS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. IQVIA
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. ICON Plc
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Laboratory Corporation of America Holdings
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Charles River Laboratories International Inc.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. PAREXEL International Corp.
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Syneos Health
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Medpace
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Holdings Inc.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. PPD Inc.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Novotech
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
10.13. Veristat LLC
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies